Jared Allenbach - Recursion Pharmaceuticals Director Relations
| RXRX Stock | USD 7.46 0.81 9.79% |
Insider
Jared Allenbach is Director Relations of Recursion Pharmaceuticals
| Address | 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 |
| Phone | 385 269 0203 |
| Web | https://www.recursion.com |
Recursion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7849) %, meaning that it created substantial loss on money invested by shareholders. Recursion Pharmaceuticals' management efficiency ratios could be used to measure how well Recursion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Recursion Pharmaceuticals' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 226.3 M in 2024, whereas Total Assets are likely to drop slightly above 520.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Uwe Reusch | Affimed NV | N/A | |
| MA MBA | Relay Therapeutics | 48 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Thomas Catinazzo | Relay Therapeutics | 48 | |
| Jonathan MS | Absci Corp | N/A | |
| Sunil MD | Sana Biotechnology | 54 | |
| JD MBA | Immix Biopharma | N/A | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Alexander Fudukidis | Affimed NV | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| CPA CPA | Absci Corp | 65 | |
| Denise Mueller | Affimed NV | 54 | |
| MBA IV | Enveric Biosciences | 68 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Andreas Busch | Absci Corp | 61 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.36 |
Recursion Pharmaceuticals Leadership Team
Elected by the shareholders, the Recursion Pharmaceuticals' board of directors comprises two types of representatives: Recursion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Recursion. The board's role is to monitor Recursion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Recursion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Recursion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Gibson, CEO CoFounder | ||
| Kevin Leggat, Vice Accounting | ||
| Janelle Gordon, Vice Operations | ||
| Ben Taylor, CFO UK | ||
| Shafique MD, Interim Officer | ||
| Nathan Hatfield, Chief Officer | ||
| Tina Larson, COO President | ||
| MBA JD, Chief Counsel | ||
| Michael Secora, Chief Officer | ||
| Kristen MBA, Chief Officer | ||
| David Hallett, Chief Officer | ||
| Jared Allenbach, Director Relations | ||
| Blake Borgeson, CoFounder Director | ||
| Ryan Kelly, Chief Officer | ||
| Benjamin MS, Chief Officer | ||
| Matthew Kinn, Chief Initiatives |
Recursion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Recursion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (3.77) % | ||||
| Current Valuation | 2.88 B | ||||
| Shares Outstanding | 381.9 M | ||||
| Shares Owned By Insiders | 3.45 % | ||||
| Shares Owned By Institutions | 69.40 % | ||||
| Number Of Shares Shorted | 67.85 M | ||||
| Price To Book | 5.53 X | ||||
| Price To Sales | 49.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.